Use of medications to reduce cardiovascular risk among individuals with psychotic disorders and Type 2 diabetes - Wikidata - awgldk - TriplyDB

Use of medications to reduce cardiovascular risk among individuals with psychotic disorders and Type 2 diabetes

Use of medications to reduce cardiovascular risk among individuals with psychotic disorders and Type 2 diabetes

http://www.wikidata.org/entity/Q35049901

about

Quality of medical care for persons with serious mental illness: A comprehensive review Impact of mental health visits on healthcare cost in patients with diabetes and comorbid mental health disorders Mental comorbidity and quality of diabetes care under Medicaid: a 50-state analysis.Risk factors for dementia in patients over 65 with diabetes.Outreach visits by clinical pharmacists improve screening for the metabolic syndrome among mentally ill patients.Risk factors for dementia with type 2 diabetes mellitus among elderly people in China.Severe mental illness and chronic kidney disease: a cross-sectional study in the United Kingdom.Cardiovascular Risk Factors in Patients with Schizophrenia Receiving Continuous Medical Care

P2860

Q27026165-BEEC9C19-0F57-4E7E-A431-488B137A203C Q33989449-4E097281-7360-41BE-821B-21EDF96E7FEC Q35989611-F1EAF39F-8F22-4A35-9262-EE4BF23D3E88 Q44096894-FDB4E000-8338-462C-BE72-51B55108DDD7 Q50898947-DA1F49D3-AF8C-4020-84D0-58A4159FA3CB Q51282260-C53DD26F-9119-41EE-BD8C-5015C39923B1 Q55322969-1C0C1024-1474-463E-AF14-30BD062B383B Q57388359-7410FFCA-FE4F-4194-B7BE-20EEF5767377

P2860

Use of medications to reduce cardiovascular risk among individuals with psychotic disorders and Type 2 diabetes

http://www.wikidata.org/entity/Q35049901

description

2008 nî lūn-bûn

@nan

2008 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի մարտին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

name

Use of medications to reduce c ...... disorders and Type 2 diabetes

@ast

Use of medications to reduce c ...... disorders and Type 2 diabetes

@en

type

label

Use of medications to reduce c ...... disorders and Type 2 diabetes

@ast

Use of medications to reduce c ...... disorders and Type 2 diabetes

@en

prefLabel

Use of medications to reduce c ...... disorders and Type 2 diabetes

@ast

Use of medications to reduce c ...... disorders and Type 2 diabetes

@en

P1433

Q35049901-712D7D2A-F4BF-48A7-A0A8-25347D5BACF6

P1476

Q35049901-3BD9E413-4361-4CB4-BB89-6B3842963EB4

P2093

Q35049901-046D97B4-A090-479C-87B7-0D9470F73562

Q35049901-405B8D8D-5F9A-443A-B21D-0344E6D46E98

Q35049901-97C96588-489E-4C34-8404-C2C8990306E2

Q35049901-CB4EC427-3A23-40AB-871E-5A18501B1461

P2860

Q35049901-04E9E29B-F183-43F3-B626-5122548644B1

Q35049901-078E8EA3-7DF9-44A1-8609-A3305A8806E4

Q35049901-0ADF95AA-C61D-4A25-AB7B-F440C6B981EB

Q35049901-2622E4DA-E9DF-4CED-ACCB-5AFC7AEB6D94

Q35049901-2C82FD4B-1B9C-4D00-BDF7-60C3054B75ED

Q35049901-2E7BA46C-3276-402B-A42A-467BBAA3B1C0

Q35049901-31903FC5-8D52-4DCF-9B51-97B3916D9C8F

Q35049901-3AD73C79-DEDC-463F-B674-DA0AFFA3BFEF

Q35049901-3B859FD5-5682-492C-9CE4-EFB4E78FEE3B

Q35049901-4DEE961C-EB64-4201-9623-7E219C1864B2

P304

Q35049901-9576920B-F782-4D49-A79D-78FFBE8F8E00

P31

Q35049901-E039EC13-636D-4AFF-9995-C7D4EC6B3989

P356

Q35049901-F89B130A-C2CB-4CDA-A9E3-577CB31834B4

P407

Q35049901-ED178A08-6C2B-422B-BD6F-697E12A8E87C

P433

Q35049901-973A386A-0AAE-46CB-A05F-D332E5ACB2BA

P478

Q35049901-12550173-FB61-424C-A658-1AE5813FFC91

P577

Q35049901-81D47204-F6D9-403B-AD74-EDACAC4D1CE0

P5875

Q35049901-07D24909-1F4E-4E10-A362-B81D9FC0D76F

P698

Q35049901-0DBC3207-2612-42E6-9942-1217B41D8671

P921

Q35049901-022C8CAF-ABD5-43B0-B598-B92D4323E0E4

Q35049901-FF3D77B7-A5FB-41FE-A9F9-760C1E1A03CB

P932

Q35049901-AC9846A2-1A96-4766-AFAA-C292D84FEF01

P356

J.SCHRES.2008.02.004

P1433

Schizophrenia Research

P1476

Use of medications to reduce c ...... disorders and Type 2 diabetes

@en

P2093

Deborah R Medoff

http://www.w3.org/2001/XMLSchema#string

Julie Kreyenbuhl

http://www.w3.org/2001/XMLSchema#string

Lisa B Dixon

http://www.w3.org/2001/XMLSchema#string

Stephen L Seliger

http://www.w3.org/2001/XMLSchema#string

P2860

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

Who has diabetes? Best estimates of diabetes prevalence in the Department of Veterans Affairs based on computerized patient data.

Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: data from the CATIE schizophrenia trial sample at baseline.

Causes of the excess mortality of schizophrenia.

Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review.

A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls.

Narrative review: lack of evidence for recommended low-density lipoprotein treatment targets: a solvable problem.

Standards of medical care in diabetes--2007.

Indications for and utilization of ACE inhibitors in older individuals with diabetes. Findings from the National Health and Nutrition Examination Survey 1999 to 2002

Use of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in high-risk clinical and ethnic groups with diabetes.

P304

256-265

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.SCHRES.2008.02.004

http://www.w3.org/2001/XMLSchema#string

P407

P433

1-3

http://www.w3.org/2001/XMLSchema#string

P478

101

http://www.w3.org/2001/XMLSchema#string

P577

2008-03-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5498122

http://www.w3.org/2001/XMLSchema#string

P698

18353616

http://www.w3.org/2001/XMLSchema#string

P921

type-2 diabetes

P932

3116690

http://www.w3.org/2001/XMLSchema#string